![Benjamin Kreitman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Benjamin Kreitman
Directeur/Membre du Conseil chez HAYA Therapeutics SA
Postes actifs de Benjamin Kreitman
Sociétés | Poste | Début | Fin |
---|---|---|---|
Broadview Ventures, Inc.
![]() Broadview Ventures, Inc. Investment ManagersFinance Broadview Ventures, Inc. (Broadview Ventures) is a venture capital firm founded in 2008. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01/01/2021 | - |
HAYA Therapeutics SA
![]() HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Benjamin Kreitman
Anciens postes connus de Benjamin Kreitman
Sociétés | Poste | Début | Fin |
---|---|---|---|
Monitor Deloitte
![]() Monitor Deloitte Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Monitor Deloitte is a company that provides strategic consulting services. The company is based in Rosslyn, VA. The company was founded by Lene S Schulze. | Consultant / Advisor | - | - |
Kantum Pharma, Inc.
![]() Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH. | Directeur/Membre du Conseil | - | - |
Formation de Benjamin Kreitman
The Trustees of Columbia University in The City of New York | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 5 |
Suisse | 2 |
Opérationnelle
Director/Board Member | 2 |
Private Equity Investor | 1 |
Undergraduate Degree | 1 |
Sectorielle
Commercial Services | 3 |
Consumer Services | 2 |
Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 4 |
---|---|
Broadview Ventures, Inc.
![]() Broadview Ventures, Inc. Investment ManagersFinance Broadview Ventures, Inc. (Broadview Ventures) is a venture capital firm founded in 2008. The firm is headquartered in Boston, Massachusetts. | Finance |
Monitor Deloitte
![]() Monitor Deloitte Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Monitor Deloitte is a company that provides strategic consulting services. The company is based in Rosslyn, VA. The company was founded by Lene S Schulze. | Commercial Services |
Kantum Pharma, Inc.
![]() Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH. | Commercial Services |
HAYA Therapeutics SA
![]() HAYA Therapeutics SA BiotechnologyHealth Technology HAYA Therapeutics SA is a Swiss precision medicines company that focuses on developing programmable therapeutics targeting regulatory RNAs derived from the dark genome to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The company's discovery engine identifies novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA's lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting WISPER that is a heart-specific lncRNA known to be a fundamental regulator of pathological cardiac fibrosis in the context of heart failure. The company is headquartered at the Life Sciences Park Biopôle in Lausanne, CH, with laboratory facilities at JLABS @ San Diego. The company was founded by Samir Ounzain and Daniel Blessing, and Samir Ounzain has been the CEO since incorporation. | Health Technology |
- Bourse
- Insiders
- Benjamin Kreitman
- Expérience